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用 18F 标记制得 PET 探针[18F]AlF-NOTA-G-TMTP1。[18F]AlF-NOTA-G-TMTP1
标记产率为(25±6)%(n=5)，放化纯大于 95%，放射性比活度大于 11.1 GBq/μmol，
脂水分配系数为-3.17±0.02。[18F]AlF-NOTA-G-TMTP1 注射到荷瘤裸鼠中 30 min
后，在 SMCC-7721 和 HCCLM3 高转移潜能肿瘤模型中，肿瘤/肌肉摄取比值大
于 4，而在 HepG2 和 HCC97L 低转移潜能肿瘤模型中，肿瘤/肌肉摄取比值小于
2。通过过量的 G-TMTP1 对[18F]AlF-NOTA-G-TMTP1 的抑制，结果 SMCC-7721




要原因，EGFR 作为重要的肿瘤治疗靶点，目前虽然有靶向 EGFR 的治疗药物，
但是却没有可以准确、全面预测这些药物疗效的临床评价指标。本研究通过固相
合成 NOTA-D4，并利用 18F 标记制得 PET 探针［18F］AlF-NOTA-D4。［18F］
AlF-NOTA-D4 标记产率为 23±5% (n=5)，放化纯大于 95%，放射性比活度大于
10.7 GBq/μmol，脂水分配系数为-0.98±0.01。通过 A549 肺癌细胞系分别建立了
皮下瘤模型和原位肺癌模型，并对其进行了 microPET/CT 显像研究发现，在尾
静脉注射 40 min后，肿瘤部位对[18F]AlF-NOTA-D4的摄取值可以达到 1.4% ID/g，
肿瘤/肌肉比值可以达到 9.2，利用过量的 D4 对[18F]AlF-NOTA-D4 抑制发现 A549
皮下瘤对[18F]AlF-NOTA-D4 的摄取降低了 53.5%，证明其具有良好的特异性。
通过对 A549 原位肺癌模型鼠的 microPET/CT 显像研究发现，随着肿瘤接种时间
的增加，肿瘤的摄取值越来越高（从 0.7% ID/g，到 2.2% ID/g），肿瘤/肝脏摄取


















阳性等。RGD 可特异性的靶向整合素 αvβ3，18F-Alfatiade 为 RGD 的二聚体，对
整合素αvβ3 的选择性高，特异性好。本研究主要探讨 18F-Alfatiade 对肿瘤的诊断
作用，旨在提供临床前药效学资料。18F-Alfatide 在肿瘤中的摄取在 10 min 左右
达到最高值，在 40 min 左右时 T/NT 比值最高，可以对αvβ3 表达可以进行半定量
的反映。我们发现 18F-Alfatide 用于 A549 原位肺癌诊断时，肿瘤部位与心脏摄取




相关，[18F]MPPF 是 5HT1A 的拮抗剂，可定量测定 5HT1A 在人脑中的分布及检
测 5-HT 的变化。我们成功实现了对[18F]MPPF 的自动化合成，合成时间约为
70min，放射化学产率为 13.2±5.9%（未经衰减矫正，n=5），放射化学纯度大于
98%，比活度高于 2×1011Bq/μmol。对大鼠脑部进行显像发现，中缝核摄取SUVmax
值为 2.15±0.21，左右颞叶皮层 SUVmax 值分别为 1.67±0.18、1.71±0.23，与





















Due to their favorable pharmacokinetics and biological activities, small peptides 
labeled with positron emitting radionuclides have shown great potential in PET 
imaging. In this study, a series of 18F-labeled peptides were synthesized and 
radiolabeled with 18F using NOTA-AlF chelation method. The biological activities of 
these tracers were evaluated in vitro and in vivo. The thesis consists of four major 
sections. 
Ⅰ. Hepatocellular carcinoma (HCC) is one of the most common and aggressive 
cancers worldwide, there was no efficient approaches for diagnosis and treatment of 
HCC metastases or postsurgical recurrence. [18F]AlF-NOTA-G-TMTP1 was 
synthesized and radiolabeled with 18F using NOTA-AlF chelation method. The total 
synthesis time was about 20 min with radiochemical yield of 25±6%. The specific 
activity was about 11.1-14.8 GBq/μmol. The log P value of 
[18F]AlF-NOTA-G-TMTP1 was -3.166±0.022. [18F]AlF-NOTA-G-TMTP1 
accumulated in SMCC-7721 and HCCLM3 tumors (high metastatic potential) in vivo 
to give tumor/muscle (T/M) ratios above 4 as measured by PET at 30 min 
post-injection (p.i.), meanwhile the tumor/muscle (T/M) ratios of HepG2 and 
HCC97L tumors which exhibited low metastatic potential were below 2. In addition, 
Uptake of the tracer in the tumor at 40 min p.i. could be inhibited 61.9% and 57.6% 
by unlabeled G-TMTP1 in SMCC-7721 and HCCLM3 tumor bearing nude mice 
respectively. [18F]AlF-NOTA-G-TMTP1 may specifically target high metastatic 
or/and aggressive hepatocellular carcinoma with low liver uptake and should be 
further evaluated clinically. 
Ⅱ. Lung cancer is one of the most common cancers in the world. There were 
several Drugs that target EGFR used to treat non-small cell lung cancer (NSCLC), 
however, there was no objective method to accurately and reliably predict the 
sensitivity of patients to anti-EGFR treatments. [18F]AlF-NOTA-D4 was synthesized 
and radiolabeled with 18F using NOTA-AlF chelation method. The total synthesis time 















10.7 GBq/μmol. The log P value of [18F]AlF-NOTA-D4 was -0.98±0.01. The 
tumor-targeting characteristics of [18F]AlF-NOTA-D4 was assessed in A549 
xenografts and A549 orthotopic lung cancer model. [18F]AlF-NOTA-D4 accumulated 
in A549 xenografts in vivo to give tumor/muscle (T/M) ratios of 9.2 as measured by 
PET at 40 min post-injection (p.i.). Uptake of the tracer in the tumor at 40 min p.i. 
could be inhibited 53.5% by unlabeled D4 in A549 tumor bearing nude mice. In 
addition, there was a dramatic increase in tumor uptake of [18F]AlF-NOTA-D4 as the 
A549 orthotopic tumor growth, the tumor/liver (T/L) ratios increased from 0.36 to 
1.98 in 15 days. Overall, [18F]AlF-NOTA-D4 could specifically target EGFR and 
should be further evaluated clinically.  
Ⅲ. With 18F-FDG, PET/CT is rapidly becoming the key investigative tool for 
the diagnosis, staging, and monitoring treatment of cancers, however, there are 
inherent limitations of 18F-FDG PET that can result in false-negative and 
false-positive findings. RGD peptides are well-known to bind preferentially to the 
αvβ3 integrin, 18F-Alfatiade a novel dimeric RGD peptide could specific target αvβ3 
integrin. The goal of this study is to evaluate the tumor-targeting characteristics of 
18F-Alfatiade and provide pharmacodynamics and pharmacokinetics materials for 
clinical trials. The tumor uptake of 18F-Alfatiade reached a peak at 10 min, and T/NT 
ratios reached a peak at 40 min. The tumor/heart ratio was 4.5 using 18F-Alfatide for 
detection of A549 orthotopic tumor which was much higher than FDG. These results 
lead to an easy approach for the diagnosis of lung cancer. Biodistribution data largely 
corroborated the microPET/CT imaging studies. 
Ⅳ. 5-HT has been implicated in mechanisms of anxiety and depression for many 
years, [18F]MPPF is a selective serotonin-1A (5-HT1A) receptor antagonist and may 
be used to measure changes in the functional levels of serotonin (5-HT). [18F]MPPF 
was synthesized automatically with a radiochemical yield of 13.2±5.9% in 70 min. 
The specific activity was above 2×1011Bq/μmol, and the radiochemical purity was 
above 95%. The in vivo distributions of [18F]MPPF was evaluated in the rat brain. 















±0.21) and cingulate cortex (SUVmax 1.67±0.18、1.71±0.23), which closely 
matched the 5-HT(1A) receptors rich areas in rat brain. These results indicate that 
[18F]MPPF could be a useful candidate for noninvasive PET imaging of 5-HT(1A) 
receptors in the living human brain. 
Overall, a series of 18F-labeled peptides have been developed, the encouraging 
preliminary data of this study indicate that further clinical evaluation of those tracers 
is warranted. 
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各种分子影像技术的特点汇总如表 1.1 所示[8]： 





灵敏度 c 探针用量 
PET 高能γ射
线 
























2-5 mm 1-2 cm sec- mins 10-9-10-17 
mol/L 
毫克-微克
MRI 电磁波 25-100 μ
m 
不限 mins-hrs 10-3-10-5 
mol/L 
毫克-微克
CT X 射线 50-200 μ
m 
不限 mins 未定 无 
超声 高频声波 50-500 μ
m 
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